Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics

Ongoing monitoring of neuroleptic-induced extrapyramidal side effects (EPS) is important to maximize treatment outcome, improve medication adherence and reduce re-hospitalization. Traditional approaches for assessing EPS such as Parkinsonism, tardive akathisia, or dyskinesia rely upon clinical ratings. However, these observer-based EPS severity ratings can be unreliable and are subject to examiner bias. In contrast, quantitative instrumental methods are less subject to bias. Most instrumental methods have only limited clinical utility because of their complexity and costs. This paper describes an easy-to-use instrumental approach based on handwriting movements for quantifying EPS. Here, we present findings from psychiatric patients treated with atypical (second generation) antipsychotics. The handwriting task consisted of a sentence written several times within a 2 cm vertical boundary at a comfortable speed using an inkless pen and digitizing tablet. Kinematic variables including movement duration, peak vertical velocity and the number of acceleration peaks, and average normalized jerk (a measure of smoothness) for each up or down stroke and their submovements were analyzed. Results from 59 psychosis patients and 46 healthy comparison subjects revealed significant slowing and dysfluency in patients compared to controls. We observed differences across medications and daily dose. These findings support the ecological validity of handwriting movement analysis as an objective behavioral biomarker for quantifying the effects of antipsychotic medication and dose on the motor system.

[1]  Y. Kao Yang,et al.  Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population‐based Study , 2007, Clinical pharmacology and therapeutics.

[2]  J. Lohr,et al.  Quantitative instrumental measurement of tardive dyskinesia: a review. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[3]  R. Regenthal,et al.  D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. , 2005, International journal of clinical pharmacology and therapeutics.

[4]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[5]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[6]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[7]  L. Cronbach Coefficient alpha and the internal structure of tests , 1951 .

[8]  William J. Marks,et al.  Deep Brain Stimulation Management: Abnormal Involuntary Movement Scale , 2010 .

[9]  A. Seese,et al.  Verkleinerung der Handschriftfläche und D2-Dopaminrezeptorblockade Ergebnisse unter Behandlung mit typischen und atypischen Neuroleptika , 2000, Der Nervenarzt.

[10]  J. Arnt Pharmacological differentation of classical and novel antipsychotics , 1998, International clinical psychopharmacology.

[11]  Hans-Leo Teulings,et al.  Digital recording and processing of handwriting movements , 1984 .

[12]  F G Paas,et al.  Effects of age and gender on discrete and reciprocal aiming movements. , 1996, Psychology and aging.

[13]  Hermann-Josef Gertz,et al.  Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs , 1999, Psychiatry Research: Neuroimaging.

[14]  R. Mcquade,et al.  Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine , 2006, Psychopharmacology.

[15]  B. Roth,et al.  Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. , 2006, CNS drug reviews.

[16]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[17]  H Wetzel,et al.  Extrapyramidal Symptoms and their Relationship to Clinical Efficacy under Perphenazine Treatment* , 1991, Pharmacopsychiatry.

[18]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[19]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[20]  G. Stelmach,et al.  Parkinsonism Reduces Coordination of Fingers, Wrist, and Arm in Fine Motor Control , 1997, Experimental Neurology.

[21]  F. Tarazi,et al.  Effects of Newer Antipsychotics on Extrapyramidal Function , 2002, CNS Drugs.

[22]  John L. Bradshaw,et al.  Kinematic analysis of handwriting movements in Schizophrenic patients , 1997, Biological Psychiatry.

[23]  Jeffrey A. Lieberman,et al.  Extrapyramidal side-effects of antipsychotics in a randomised trial , 2008, British Journal of Psychiatry.

[24]  R. Tandon,et al.  Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome , 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[25]  S. Marder,et al.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials , 2003, Schizophrenia Research.

[26]  R. Kessler Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? , 2007, The American journal of psychiatry.

[27]  J. Kane,et al.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.

[28]  T. Barnes A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[29]  Hans-Leo Teulings,et al.  Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. , 2006, Human movement science.

[30]  Haase Hj Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. , 1961 .

[31]  D. Jeste,et al.  Antipsychotic-Induced Movement Disorders in the Elderly , 2000, Drugs & aging.

[32]  R A Abrams,et al.  Optimality in human motor performance: ideal control of rapid aimed movements. , 1988, Psychological review.

[33]  Hans-Leo Teulings,et al.  Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. , 2009, Human movement science.

[34]  P. Weiden EPS Profiles: The Atypical Antipsychotics: Are Not All the Same , 2007, Journal of psychiatric practice.